Tolvaptan
Bharath Rangarajan1, Vineetha Binoy1, Sachin Sharatchandra Hingmire2
1Department of Medical Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka, India.
Abstract:
Hyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan. Vaptans including Tolvaptan act as "aquaretic" agents cousing excretion of water while retaining the sodium. Administration of this agent for prescribed periods result in improvement of serum sodium levels. The drug can be used in many clinical situations resulting in hyponatremia including congestive heart failure, cirrhosis and syndrome of inappropriate ADH secretion (SIADH) including SIADH related to malignancies.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Renal Drug Excretion: Tubular Secretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antihypertensive Drugs: Angiotensin II Receptor Blockers


